Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotics for Prevention of Systemic Infection in Critically Ill Patients
NCT07164781Enrolling by invitation
- Sponsor
- Benha University
- Start
- Apr 2025
- Primary completion
- Sep 2025
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of bacillus clausii in systemic infection, ventilator-associated pneumonia (VAP), catheter-related bloodstream infection (CRBSI) and 1 more (2 arms), sponsored by Benha University. Primary endpoint: Occurrence of systemic infections at 1 month. Started Apr 2025; status: enrolling by invitation.
02
Drugs
bacillus clausii
03
Conditions
systemic infectionventilator-associated pneumonia (VAP)catheter-related bloodstream infection (CRBSI)urinary tract infection (UTI)
Beyond the preview
Go deeper on NCT07164781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07164781.